Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipients

Yael Peled, Arnon Afek, Jignesh K. Patel, Ehud Raanani, Amit Segev, Eilon Ram, Alexander Fardman, Roy Beigel, Menucha Jurkowicz, Nofar Atari, Limor Kliker, Ital Nemet, Michal Mandelboim

Research output: Contribution to journalArticlepeer-review

Abstract

Continued circulation of severe acute respiratory syndrome coronavirus 2 has driven the selection of variants with improved ability to escape preexisting vaccine-induced responses, posing a persistent threat to heart transplant recipients (HTRs). The immunogenicity and safety of the updated XBB.1.5-containing monovalent vaccines are unknown. We prospectively enrolled 52 HTRs who had previously received a 5-dose ancestral-derived monovalent and bivalent messenger RNA (mRNA) vaccination schedule to receive the monovalent XBB.1.5 vaccine. Immunogenicity was evaluated using live virus microneutralization assays. The XBB.1.5 monovalent vaccine elicited potent and diverse neutralizing responses and broadened the reactivity spectrum to encompass newer strains, with the highest increase in neutralization activity being more pronounced against XBB.1.5 (15.8-fold) and JN.1 (13.3-fold) than against BA.5 (6.7-fold) and wild-type (4-fold). Notably, XBB.1.5 and JN.1 were resistant to neutralization by prevaccination sera. There were no safety concerns. Our findings support the updating of coronavirus disease 2019 vaccines to match antigenically divergent variants and exclude ancestral spike-antigen to protect HTRs.

Original languageEnglish
Pages (from-to)1188-1192
Number of pages5
JournalJournal of Heart and Lung Transplantation
Volume43
Issue number7
Early online date24 Mar 2024
DOIs
StatePublished - Jul 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2024 International Society for the Heart and Lung Transplantation

Keywords

  • XBB.1.5 variant
  • coronavirus disease 2019
  • heart transplantation
  • monovalent vaccine
  • sixth dose

Fingerprint

Dive into the research topics of 'Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipients'. Together they form a unique fingerprint.

Cite this